…, as is the stress caused by any delays. Every effort should be made to expedite their publication. Research currently takes far too long and any attempt to speed up the process is welcome. Time is a commodity those with Parkinson's do not have”.
Take home message: The best comparative study suggests that there is not much to choose between the different classes of Parkinson’s medication in terms of symptom control and quality of life in the early stages. We still need better evidence on longer term effectiveness.
Despite its limitations, researchers have found ways to maximise the benefit of levodopa, getting better symptom control for longer, while limiting its side effects. However, as more brain cells are lost over time, larger doses and more drugs are needed to achieve the same symptom control, and this means more side effects. And none of these medications can slow the progression of Parkinson’s.